599 related articles for article (PubMed ID: 29228918)
1. Nevirapine- versus Efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and Tuberculosis infections in India: a multi-centre study.
Sinha S; Gupta K; Tripathy S; Dhooria S; Ranjan S; Pandey RM
BMC Infect Dis; 2017 Dec; 17(1):761. PubMed ID: 29228918
[TBL] [Abstract][Full Text] [Related]
2. Nevirapine versus efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and tuberculosis infections in India: a pilot study.
Sinha S; Raghunandan P; Chandrashekhar R; Sharma SK; Kumar S; Dhooria S; Ekka M; Velpandian T; Ranjan S; Ahmad H; Samantaray JC; Venkatesh S; Rewari BB; Khan NH; Pandey RM
BMC Infect Dis; 2013 Oct; 13():482. PubMed ID: 24134449
[TBL] [Abstract][Full Text] [Related]
3. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.
Manosuthi W; Sungkanuparph S; Tantanathip P; Lueangniyomkul A; Mankatitham W; Prasithsirskul W; Burapatarawong S; Thongyen S; Likanonsakul S; Thawornwa U; Prommool V; Ruxrungtham K;
Clin Infect Dis; 2009 Jun; 48(12):1752-9. PubMed ID: 19438397
[TBL] [Abstract][Full Text] [Related]
4. Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a systematic review and meta-analysis.
Jiang HY; Zhang MN; Chen HJ; Yang Y; Deng M; Ruan B
Int J Infect Dis; 2014 Aug; 25():130-5. PubMed ID: 24911886
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy.
Boulle A; Van Cutsem G; Cohen K; Hilderbrand K; Mathee S; Abrahams M; Goemaere E; Coetzee D; Maartens G
JAMA; 2008 Aug; 300(5):530-9. PubMed ID: 18677025
[TBL] [Abstract][Full Text] [Related]
6. Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial.
Bonnet M; Bhatt N; Baudin E; Silva C; Michon C; Taburet AM; Ciaffi L; Sobry A; Bastos R; Nunes E; Rouzioux C; Jani I; Calmy A;
Lancet Infect Dis; 2013 Apr; 13(4):303-12. PubMed ID: 23433590
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial.
Swaminathan S; Padmapriyadarsini C; Venkatesan P; Narendran G; Ramesh Kumar S; Iliayas S; Menon PA; Selvaraju S; Pooranagangadevi NP; Bhavani PK; Ponnuraja C; Dilip M; Ramachandran R
Clin Infect Dis; 2011 Oct; 53(7):716-24. PubMed ID: 21890776
[TBL] [Abstract][Full Text] [Related]
8. Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin.
Manosuthi W; Mankatitham W; Lueangniyomkul A; Chimsuntorn S; Sungkanuparph S
HIV Med; 2008 May; 9(5):294-9. PubMed ID: 18400076
[TBL] [Abstract][Full Text] [Related]
9. Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults.
Nachega JB; Hislop M; Dowdy DW; Gallant JE; Chaisson RE; Regensberg L; Maartens G
AIDS; 2008 Oct; 22(16):2117-25. PubMed ID: 18832875
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment.
Bhatt NB; Barau C; Amin A; Baudin E; Meggi B; Silva C; Furlan V; Grinsztejn B; Barrail-Tran A; Bonnet M; Taburet AM;
Antimicrob Agents Chemother; 2014 Jun; 58(6):3182-90. PubMed ID: 24663014
[TBL] [Abstract][Full Text] [Related]
11. Unintended Pregnancies Observed With Combined Use of the Levonorgestrel Contraceptive Implant and Efavirenz-based Antiretroviral Therapy: A Three-Arm Pharmacokinetic Evaluation Over 48 Weeks.
Scarsi KK; Darin KM; Nakalema S; Back DJ; Byakika-Kibwika P; Else LJ; Dilly Penchala S; Buzibye A; Cohn SE; Merry C; Lamorde M
Clin Infect Dis; 2016 Mar; 62(6):675-682. PubMed ID: 26646680
[TBL] [Abstract][Full Text] [Related]
12. Quality of life in patients treated with first-line antiretroviral therapy containing nevirapine or efavirenz in Uganda: a prospective non-randomized study.
Mwesigire DM; Wu AW; Martin F; Katamba A; Seeley J
BMC Health Serv Res; 2015 Jul; 15():292. PubMed ID: 26216221
[TBL] [Abstract][Full Text] [Related]
13. Dyslipidemia among HIV-infected Patients with tuberculosis taking once-daily nonnucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in India.
Padmapriyadarsini C; Ramesh Kumar S; Terrin N; Narendran G; Menon PA; Ramachandran G; Subramanyan S; Venkatesan P; Wanke C; Swaminathan S
Clin Infect Dis; 2011 Feb; 52(4):540-6. PubMed ID: 21252141
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of nevirapine- and efavirenz-based antiretroviral treatment in adults treated for TB-HIV co-infection in Botswana.
Shipton LK; Wester CW; Stock S; Ndwapi N; Gaolathe T; Thior I; Avalos A; Moffat HJ; Mboya JJ; Widenfelt E; Essex M; Hughes MD; Shapiro RL
Int J Tuberc Lung Dis; 2009 Mar; 13(3):360-6. PubMed ID: 19275797
[TBL] [Abstract][Full Text] [Related]
15. Early changes in hepatic function among HIV-tuberculosis patients treated with nevirapine or efavirenz along with rifampin-based anti-tuberculosis therapy.
Padmapriyadarsini C; Bhavani PK; Tang A; Kumar H; Ponnuraja C; Narendran G; Hannah E; Ramesh C; Chandrasekar C; Wanke C; Swaminathan S
Int J Infect Dis; 2013 Dec; 17(12):e1154-9. PubMed ID: 24120216
[TBL] [Abstract][Full Text] [Related]
16. Association between efavirenz-based compared with nevirapine-based antiretroviral regimens and virological failure in HIV-infected children.
Lowenthal ED; Ellenberg JH; Machine E; Sagdeo A; Boiditswe S; Steenhoff AP; Rutstein R; Anabwani G; Gross R
JAMA; 2013 May; 309(17):1803-9. PubMed ID: 23632724
[TBL] [Abstract][Full Text] [Related]
17. Long-term effectiveness of first-line non-nucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral therapy in Ghana.
Sarfo FS; Sarfo MA; Kasim A; Phillips R; Booth M; Chadwick D
J Antimicrob Chemother; 2014 Jan; 69(1):254-61. PubMed ID: 24003181
[TBL] [Abstract][Full Text] [Related]
18. Influence of ABCB-1 C3435T polymorphisms on plasma nevirapine and efavirenz levels and their effects on virologic and immunological outcomes in HIV/TB co-infected Thai adults under anti-retroviral therapy.
Uttayamakul S; Likanonsakul S; Manosuthi W; Wichukchinda N; Shioda T; Khusmith S
Southeast Asian J Trop Med Public Health; 2012 Jan; 43(1):78-88. PubMed ID: 23082557
[TBL] [Abstract][Full Text] [Related]
19. Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial.
Grinsztejn B; De Castro N; Arnold V; Veloso VG; Morgado M; Pilotto JH; Brites C; Madruga JV; Barcellos NT; Santos BR; Vorsatz C; Fagard C; Santini-Oliveira M; Patey O; Delaugerre C; Chêne G; Molina JM;
Lancet Infect Dis; 2014 Jun; 14(6):459-67. PubMed ID: 24726095
[TBL] [Abstract][Full Text] [Related]
20. The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study.
Cain LE; Phillips A; Lodi S; Sabin C; Bansi L; Justice A; Tate J; Logan R; Robins JM; Sterne JA; van Sighem A; de Wolf F; Bucher HC; Elzi L; Touloumi G; Vourli G; Esteve A; Casabona J; del Amo J; Moreno S; Seng R; Meyer L; Pérez-Hoyos S; Muga R; Abgrall S; Costagliola D; Hernán MA;
AIDS; 2012 Aug; 26(13):1691-705. PubMed ID: 22546987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
